Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-09-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: ventricularqtcancercardiacbiopsy
  Phrases that lowered it: participantsvaccinationmultipleinterfere withinvestigator
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 9.6% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 31.8% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 21 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 89.4% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 11265 (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Sponsor's past trials: 104 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study NCT04095208 · started 2020 · scored riskier than 89% of active trials completed
• Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery NCT02880020 · started 2016 · scored riskier than 74% of active trials completed
• A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers NCT02923934 · started 2017 · scored riskier than 87% of active trials completed
• Cabozantinib and Nivolumab for Carcinoid Tumors NCT04197310 · started 2019 · scored riskier than 84% of active trials completed
• A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System NCT03648372 · started 2018 · scored riskier than 60% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.